Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as...